Skip to content

Influence of Tart Cherry Juice Intervention on Vascular Function

Influence of Tart Cherry Juice Intervention on Vascular Function and the Urinary Metabolite; a Preliminary Study to Inform Study Design

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04840160
Enrollment
23
Registered
2021-04-09
Start date
2016-04-01
Completion date
2019-08-01
Last updated
2021-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dietary Exposure, Metabolic Disturbance

Keywords

cherry, anthocyanin, vascular function, metabolomics

Brief summary

Diets containing fruit rich in anthocyanins have been shown (in meta-analyses) to be beneficial for health, but intervention trials have shown inconsistent results. In this preliminary study we want to investigate the influence of a tart-cherry juice intervention on vascular function and explore metabolite profiles that may offer insight into their mechanism of action

Detailed description

Cardiovascular disease (CVD) is the primary cause of morbidity and mortality. Tart cherries (TC) can positively impact major risk factors of CVD, activities thought to be related to their phytochemical content. However, data from human trials is less clear. TC have been shown to reduce systolic blood pressure (SBP) after acute, short-term and chronic intake, and to improve vascular dysfunction, presumably due to their antioxidant and anti-inflammatory activities. Other studies have not shown benefits of TC on SBP or vascular function and studies are difficult to interpret with different populations, dosing and durations being used as well as a lack of understanding for any underlying mechanisms. To account for the latter, the use of metabolomics has become increasingly popular in nutritional research. Therefore, the aim of this preliminary study was to characterise the effects of TC supplementation on vascular function with a 4-week intervention and explore if metabolomics can provide mechanistic evidence and this will inform for future chronic studies with TC juice.

Interventions

DIETARY_SUPPLEMENTCherry juice

A tart cherry juice intervention

DIETARY_SUPPLEMENTPlacebo

A tart cherry juice placebo

Sponsors

Northumbria University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Masking description

Participants supplied with treatment or placebo in a plastic container

Intervention model description

Randomised controlled trial

Eligibility

Sex/Gender
ALL
Age
19 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* aged 19-40 * no diagnosed issues with the ability to consume fruit juice * no known food intolerances to fruits

Exclusion criteria

* participants that are cigarette smokers * participants diagnosed with hypertension * participants diagnosed with any form of cardiometabolic diseases * participants that require any prescribed prescriptions excluding the contraceptive pill * participants that are regular consumers of cherries (\>100 g/d) * participants that consume any antioxidant supplements

Design outcomes

Primary

MeasureTime frameDescription
Systolic and diastolic blood pressureChange in blood pressure following 4 weeks interventionMeasurement of systolic and diastolic blood pressure before and after the intervention
Arterial pulse wave velocityChange in pulse wave velocity following 4 weeks interventionMeasurement of pulse wave velocity before and after the intervention
Digital volume pulseChange in digital volume pulse following 4 weeks interventionMeasurement of digital volume pulse before and after the intervention

Secondary

MeasureTime frameDescription
MetabolomicsChanges to urinary metabolite profiles following 4 weeks interventionIon intensities of ca 5000 metabolites in urine samples before and after the intervention

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026